Main Article Content
Background:SARS-CoV-2 infection has caused a global pandemic that continues to negatively impact human health. A large group of microbial domains including bacteria co-evolved and interacted in complex molecular pathogenesis along with SARS-CoV-2. Evidence suggests that periodontal disease bacteria are involved in COVID-19, and are associated with chronic inflammatory systemic diseases. This study was performed to investigate the association between bacterial loads of Porphyromonas gingivalis and pathogenesis of SARS-CoV-2 infection. Fifty patients with confirmed COVID-19 by reverse transcriptase-polymerase chain reaction, their age ranges between 20-76 years, and 35 healthy volunteers (matched accordingly with age and sex to the patients) participated in this case control study. Oral hygiene status was determined by the simplified oral hygiene index. Blood and saliva samples were obtained from patients and controls, Porphyromonas gingivalis quantification from extracted DNA of blood and saliva samples performed by means of real-time polymerase chain reaction. The present result revealed that the quantity of salivary Porphyromonas gingivalis was significantly higher (p=0.003) in the patients’ group than in the controls group, while there was no significant difference in the number of bacteria in the blood samples between the two groups. Moreover, the number of bacteria in severe cases was higher than that in moderate and mild with no significant differences, and there was a significant increase in the number of bacteria among patients with poor oral hygiene compared to patients with good oral hygiene. This study demonstrated that the high level of salivary Porphyromonas gingivalis in patients increases in number with disease severity, which may indicate that bacterial infections contribute to the spread of the disease.
Received date: 15-1-2022
Accepted date: 22-3-2022
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but thatâ€™s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: im-plications for virus origins and receptor binding. Lancet 2020, 395:565–574.
Wu CP, Adhi F, Highland K. Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19. Cleve Clin J Med 2020; 2;87(11):659-663.
Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?. J Microbiol Immunol Infect 2020.
J Microbiol Immunol Infect 2020;53(4):505-512.
Li ZT, Chen ZM, Chen LD, Zhan YQ, Li SQ, Cheng J, et al. Coinfection with SARS-CoV-2 and other respiratory pathogens in patients with COVID-19 in Guangzhou, China. J Med Virol. 2020;92(11):2381-2383.
Kilian, M., Chapple, I., and Hannig, M., et al.. The oral microbiome – an update for oral healthcare professionals. Br Dent J 2016; 221: 657–66.
Chakraborty S. Metagenome of SARS-Cov2 patients in Shenzhen with travel to Wuhan shows a wide range of spe-cies-Lautropia, Cutibacterium, Haemophilus being most abundant-and Campylobacter explaining diarrhea.online 24 March 2020. Cited by Patel J. et al. The role of oral bacteria in covid-19. Lancet Microbe 2020;1(3):e105.
Patel, J. and Sampson, V. The role of oral bacteria in COVID-19. The Lancet Microbe 2020; 1(3):105.
Greene JG, Vermillion JR. The simplified oral hygiene index. The Journal of the American Dental Association 1964;68(1):7-13.
Hoque MN., Rahman MS., Ahmed R, Hossain MS., Islam MS., Crandall KA. Diversity and Genomic Determinants of the Microbiomes Associated with COVID-19 and Non-COVID Respiratory Diseases. Gene Rep 2021;23:101200.
Imai K, Ochiai K, Okamoto T. Reactivation of Latent HIV-1 Infection by the Periodontopathic Bacterium Porphyromonas gingivalis Involves Histone Modification. J Immunol 2009;182(6):3688-95.
Imai, K., Inoue, H., Tamura, M., Cueno, ME., Inoue, H., Takeichi, O, et al. The periodontal pathogen Porphyromonas gingivalis induces the Epstein–Barr virus lytic switch transactivator ZEBRA by histone modification. Biochimie 2012.;94(3):839-846.
Luo Y, Xie Y, Zhang W, Lin Q, Tang G, Wu S, et al. Combination of lymphocyte number and function in evaluating host immunity. Aging (Albany NY) 2019;11(24):12685–12707.
Wang M, Luo L, Bu H, Xia H. Case report: one case of coronavirus desease 2019 (COVID-19) in patient co-nfected by HIV with a low CD4+ T cell count. Int J Infect Dis. 2020;96:148–150.
Soffritti, I, D'Accolti, M, Fabbri, C, Passaro, A, Manfredini, R, Zuliani, G, et al. Oral microbiome dysbiosis is associated with symptoms severity and local immune/inflammatory response in COVID-19 patients: a cross-sectional study. Frontiers in micro-biology 2021; 12:1397.
Herrera, D, Serrano, J, Roldán, S, Sanz, M. Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin. Oral Investig. 2020; 24: 2925–2930.
Lloyd-Jones G, Molayem S, Pontes CC, Chapple I. The COVID-19 pathway: A proposed oral-vascular-pulmonary route of SARS-CoV-2 infection and the importance of oral healthcare measures. J Oral Med Dent Res. 2021;2(1):S1.
Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide, RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. The Lancet Respiratory Medicine 2020;8(7):681-686.
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, et al. Covid-19 in Critically Ill Patients in the Seattle Region- Case Series. N Engl J Med 2020;382(21):2012-22.